Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Presents Preclinical Data Demonstrating Reduction of Inflammation Using New Drug Candidate for Eczema
May 9, 2005
|
69.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that its NF-kappaB Decoy (NF-kB Decoy) drug candidate demonstrated a dramatic decrease in inflammation and swelling in preclinical models of atopic dermatitis, a chronic inflammatory skin disease also known as eczema. NF-kB...
|
|
|
Corgentech to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
Apr 29, 2005
|
65.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that Richard P. Powers, the company's vice president and chief financial officer, will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference in Paris, France on Thursda...
|
|
|
Corgentech Announces First Quarter 2005 Financial Results
Apr 27, 2005
|
81.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today reported financial results for the first quarter ended March 31, 2005.
"We have acted quickly to cut expenses given the failure of E2F Decoy, and we are focusing on other exciting product candidates, which address large proven ...
|
|
|
Corgentech to Announce First Quarter 2005 Financial Results and Host Webcast Conference Call on April 27, 2005
Apr 21, 2005
|
66.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will announce financial results for the first quarter 2005 after the markets close on Wednesday, April 27, 2005 and will hold a webcast teleconference at 4:30 p.m. Eastern time that day. John McLaughlin, Corgen...
|
|
|
Corgentech Reduces Expenses and Focuses Development Efforts
Apr 19, 2005
|
67.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that it is reducing its workforce by approximately 45 percent to focus the company's resources on its most promising next-generation drug candidates in light of the failure of E2F Decoy in Phase 3 clinical trials. Corgen...
|
|
|
Click here to download our most recent fact sheet.